Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMTX 
Immatics NV (IMTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: IMTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.67
1 Year Target Price $13.67
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.88% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 707.48M USD | Price to earnings Ratio - | 1Y Target Price 13.67 |
Price to earnings Ratio - | 1Y Target Price 13.67 | ||
Volume (30-day avg) 7 | Beta 1.02 | 52 Weeks Range 3.30 - 12.56 | Updated Date 09/16/2025 |
52 Weeks Range 3.30 - 12.56 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -57.45% | Operating Margin (TTM) -1121.53% |
Management Effectiveness
Return on Assets (TTM) -9.12% | Return on Equity (TTM) -17.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 166475008 | Price to Sales(TTM) 5.44 |
Enterprise Value 166475008 | Price to Sales(TTM) 5.44 | ||
Enterprise Value to Revenue 1.09 | Enterprise Value to EBITDA 7.19 | Shares Outstanding 121560000 | Shares Floating 53889761 |
Shares Outstanding 121560000 | Shares Floating 53889761 | ||
Percent Insiders 22.85 | Percent Institutions 79.55 |
Upturn AI SWOT
Immatics NV
Company Overview
History and Background
Immatics N.V. is a clinical-stage biopharmaceutical company founded in 2000, focused on the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. It initially focused on identifying and validating cancer targets and later expanded into developing therapeutic candidates based on these targets.
Core Business Areas
- Cellular Therapies (TCER): This segment focuses on developing adoptive cell therapies using genetically engineered T-cells to target specific cancer antigens. Its lead TCER product candidate is IMA203, targeting PRAME. The company utilizes its ACTengine and ACTallo platforms to develop these cell therapies.
- Antibody-like TCR Bispecifics (TCER): This segment focuses on the development of antibody-like TCR Bispecifics, which redirect a patient's own T-cells to cancer cells. It uses XPRESIDENT platform. The lead product is IMA401.
Leadership and Structure
The leadership team includes Carsten Reinhardt as Chairman and CEO. The company has a board of directors overseeing its strategic direction. The organizational structure is typical for a biopharmaceutical company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- IMA203 (ACTengineu00ae T-Cell Therapy): A T-cell therapy targeting PRAME (PReferentially expressed Antigen in MElanoma). It is in clinical development for various solid tumors. Market share data is currently not available as it is still in clinical trials. Key competitors developing T-cell therapies for solid tumors include companies like Adaptimmune, Iovance Biotherapeutics, and TCR2 Therapeutics.
- IMA401 (TCER Bispecific): A TCR Bispecific antibody targeting PRAME. It is in clinical development for various solid tumors. Market share data is currently not available as it is still in clinical trials. Key competitors developing bispecific antibodies for solid tumors include companies like Amgen, Roche, and Regeneron.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is rapidly growing with increasing demand for targeted therapies like cell therapies and bispecific antibodies. The market is highly competitive and regulated, with significant investment in research and development.
Positioning
Immatics is positioned as a leader in developing T-cell redirecting immunotherapies, with a focus on TCR-based therapies. Its competitive advantage lies in its target discovery and TCR engineering platforms.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to be in the tens of billions of dollars. Immatics is positioned to capture a portion of this market through its innovative T-cell redirecting therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TCR discovery and engineering platforms
- Strong pipeline of T-cell redirecting immunotherapies
- Experienced management team
- Strategic partnerships with leading pharmaceutical companies
Weaknesses
- High R&D costs and long development timelines
- Clinical trial risks and regulatory hurdles
- Reliance on third-party manufacturing
- Limited commercial infrastructure
Opportunities
- Expanding the application of its therapies to new cancer types
- Advancing its pipeline through clinical development
- Partnering with larger pharmaceutical companies for commercialization
- Utilizing its technology platform to develop new therapies
Threats
- Competition from other immunotherapy companies
- Failure of clinical trials
- Changes in regulatory landscape
- Pricing pressure from payers
Competitors and Market Share
Key Competitors
- ADAP
- IOVA
- TCRR
Competitive Landscape
Immatics has a competitive advantage in its TCR-based therapies and target discovery platform. However, it faces competition from larger, more established immunotherapy companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advancements in its clinical pipeline and strategic partnerships.
Future Projections: Future growth is projected to be driven by the potential approval and commercialization of its lead product candidates.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its manufacturing capabilities, and strengthening its strategic partnerships.
Summary
Immatics NV is a promising clinical-stage biopharmaceutical company focused on T-cell redirecting immunotherapies. Its proprietary TCR discovery platform and strong pipeline position it well for future growth. However, the company faces challenges related to clinical trial risks and competition in the crowded immunotherapy market. Its strategic partnerships are key to its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on publicly available information and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immatics NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-02 | CEO, MD, Member of Management Board & Executive Director Dr. Harpreet Singh Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 554 | Website https://www.immatics.com |
Full time employees 554 | Website https://www.immatics.com | ||
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. was founded in 2020 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.